False Claims Act Recoveries After Government Declination: Billions From Cases Whistleblowers Carried

False Claims Act declined cases statistics show billions of dollars in settlements and judgments in cases the government did not take over. If you know how a company turned sales targets, physician payments or false billing into government money, those national totals are background. Your knowledge of the conduct is what gives a case its substance.

Can I Proceed After Declination?

Yes. A whistleblower can continue a case after the government declines. Declination means the government has elected not to take over the case. It does not decide whether the allegations are true. The whistleblower and the False Claims Act whistleblower lawyers carry the case forward.

That role is part of the law’s design. Qui Tam: The False Claims Act and Related Federal Statutes, the Congressional Research Service’s 2009 report, describes how the 1986 amendments strengthened private enforcement in response to extensive fraud against the government. The public can bring a case in the government’s name and share in the recovery.

Government intervention can also happen later. The annual tables distinguish cases the United States intervened in or otherwise pursued from cases it declined. The results below show why we would never treat declination as a company’s clean bill of health.

Fiscal 2025 False Claims Act Recoveries

The Department of Justice reported $6,888,096,266 in total settlements and judgments for fiscal 2025, including $5,340,006,336 from qui tam cases brought by whistleblowers. Those figures appear in the statistical tables accompanying its annual announcement, published January 16, 2026.

The same edition reports 1,297 new qui tam matters. Those are new cases entering the system. The settlement-and-judgment dollars can come from cases filed in earlier years.

Why Declined-Case Recoveries Jump Around

Declined-case recoveries change sharply with the cases reaching an outcome. The Department of Justice’s fiscal 2025 edition puts the recent years side by side:

In the first year shown, declined cases produced more settlement-and-judgment dollars than government-pursued qui tam cases. In the next two, the relationship went the other way. A large case reaching judgment can move the annual number substantially. That is why a single year’s dollars make a poor verdict on the value of whistleblowers carrying their own cases.

The Janssen Judgment Behind the Annual Headline

Janssen Products shows how one declined case can account for a large part of a fiscal year’s total. The Department of Justice’s fiscal 2025 fact sheet identified its $1.6 billion trial result among the cases whistleblowers pursued themselves.

The underlying case concerned promotion of Prezista and Intelence, drugs for HIV/AIDS. In its March 28, 2025 opinion, the court described the jury’s finding that unlawful promotion caused 159,574 false claims. The False Claims Act judgment included tripled federal damages and a civil penalty for each false claim. A repeated practice, multiplied across claims, produced the headline.

The whistleblowers’ complaint describes what that promotion allegedly looked like inside the business. It alleged that paid speakers received higher fees as their prescribing share increased and that low prescribers could lose their speaking roles. It also alleged that supposedly educational dinners could be steered from the audience:

The company allegedly staged the questions as well as supplying the answers. For someone who worked in sales, the useful details are the speaker selection, prescribing reports and instructions behind the dinner.

CVS Caremark supplied another large privately pursued result. The August 19, 2025 judgment ordered CVS Caremark businesses to pay $289,873,500 after a trial before a judge.

Healthcare Dominates the Declined Dollars

Health care accounted for nearly all the declined-case dollars in fiscal 2025. The Department of Health and Human Services category recorded $2,274,416,048, compared with $8,006,796 for Defense and $5,848,662 for Other.

The pharmaceutical cases show how sales practices can reach the government’s bill. Janssen’s unlawful promotion caused false claims. The Biogen allegations below concern payments to physicians who prescribed drugs covered by Medicare and Medicaid. An insider in those businesses may see the sales incentives long before seeing the government claim.

Biogen’s Settlement Shows the Federal Share

Biogen agreed to a $900 million settlement in September 2022 in a case pursued by a former employee. The whistleblower alleged that speaker honoraria, consulting fees, training payments and meals induced physicians to prescribe its multiple sclerosis drugs, causing false claims to Medicare and Medicaid.

The Justice Department’s announcement separated $843,805,187 for the United States from $56,194,813 for the states.

The mechanism also gives the Janssen allegations a useful parallel. Both cases put payments to prescribing physicians and pharmaceutical promotion under scrutiny. Janssen lost at trial. Biogen settled the former employee’s allegations.

What Share Is Possible?

A whistleblower case under the False Claims Act can pay 15% to 30% of what the government recovers. When the government does not proceed, the ordinary share is 25% to 30%.

The Department of Justice’s annual table separately reported $330,358,218 in whistleblower share awards for fiscal 2025.

Our whistleblower experts assess the conduct and the claims with you. The national totals show what privately pursued cases have achieved. Your evidence is where we start building yours.

The Evidence Behind Your Case

If you know the payments, sales practices or billing decisions behind false claims, speak to one of our Whistleblower Experts about building your strongest False Claims Act case. Whether you are considering coming forward or the government has already declined, we assess the opportunity with you, bring in False Claims Act whistleblower lawyers suited to pursuing the case without government intervention and stay beside you as your case moves forward.